Etofibrate: Difference between revisions
Matt Pijoan (talk | contribs) m (Protected "Etofibrate": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +)) |
||
| Line 27: | Line 27: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 36: | Line 36: | ||
{{Lipid modifying agents}} | {{Lipid modifying agents}} | ||
[[Category:Fibrates]] | [[Category:Fibrates]] | ||
[[Category:Prodrugs]] | [[Category:Prodrugs]] | ||
Revision as of 02:26, 9 August 2012
{{drugbox | IUPAC_name = 2-{[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy}ethyl nicotinate | image = Etofibrate svg.png | CAS_number = 31637-97-5 | ATC_prefix = C10 | ATC_suffix = AB09 | PubChem = 65777 | DrugBank = | C=18|H=18|Cl=1|N=1|O=5 | molecular_weight = 363.792 g/mol | bioavailability = | protein_bound = | metabolism = Hydrolyzed to clofibric acid and niacin | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }}
|
WikiDoc Resources for Etofibrate |
|
Articles |
|---|
|
Most recent articles on Etofibrate |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Etofibrate at Clinical Trials.gov Clinical Trials on Etofibrate at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Etofibrate
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Etofibrate Discussion groups on Etofibrate Patient Handouts on Etofibrate Directions to Hospitals Treating Etofibrate Risk calculators and risk factors for Etofibrate
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Etofibrate |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Etofibrate is a fibrate. It is a combination of clofibrate and niacin, linked together by an ester bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to controlled-release formulations.[1]
References
- ↑ Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA (2001). "Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects". Braz J Med Biol Res. 34 (2): 177–82. PMID 11175492. Free full text